CorMedix Inc. (CRMD)
NASDAQ: CRMD · Real-Time Price · USD
7.91
+0.36 (4.77%)
At close: May 18, 2026, 4:00 PM EDT
7.94
+0.03 (0.38%)
Pre-market: May 19, 2026, 6:54 AM EDT
CorMedix Revenue
CorMedix had revenue of $127.43M in the quarter ending March 31, 2026, with 226.05% growth. This brings the company's revenue in the last twelve months to $400.05M, up 384.60% year-over-year. In the year 2025, CorMedix had annual revenue of $311.71M with 617.03% growth.
Revenue (ttm)
$400.05M
Revenue Growth
+384.60%
P/S Ratio
1.55
Revenue / Employee
$2,094,524
Employees
191
Market Cap
620.55M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 311.71M | 268.24M | 617.03% |
| Dec 31, 2024 | 43.47M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 65.41K | -125.53K | -65.74% |
| Dec 31, 2021 | 190.94K | -48.30K | -20.19% |
| Dec 31, 2020 | 239.23K | -44.04K | -15.55% |
| Dec 31, 2019 | 283.27K | -146.53K | -34.09% |
| Dec 31, 2018 | 429.80K | 100.47K | 30.51% |
| Dec 31, 2017 | 329.33K | 105.22K | 46.95% |
| Dec 31, 2016 | 224.11K | 13.98K | 6.65% |
| Dec 31, 2015 | 210.13K | 20.86K | 11.02% |
| Dec 31, 2014 | 189.27K | 187.27K | 9,358.97% |
| Dec 31, 2013 | 2.00K | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zevra Therapeutics | 122.29M |
| Gyre Therapeutics | 117.05M |
| Crescent Biopharma | 11.88M |
| Aclaris Therapeutics | 8.37M |
| Allogene Therapeutics | 22.00K |
CRMD News
- 3 days ago - Cormedix Therapeutics to Participate in two Upcoming Investor Conferences - GlobeNewsWire
- 4 days ago - CorMedix Earnings Call Transcript: Q1 2026 - Transcripts
- 4 days ago - CorMedix Earnings release: Q1 2026 - Filings
- 4 days ago - CorMedix Quarterly report: Q1 2026 - Filings
- 4 days ago - CorMedix reports Q1 EPS 43c, consensus 33c - TheFly
- 4 days ago - CorMedix raises FY26 revenue view to $325M-$345M from $300M-$320M - TheFly
- 4 days ago - Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 13 days ago - CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026 - GlobeNewsWire